Serum sclerostin levels in rheumatoid arthritis

Ibrahim, Saad M.; Abdelsamad, Amr Mahmoud; Helmy, A.; Farouk, Naglaa

doi:10.1016/j.injr.2015.05.002

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the association between serum sclerostin concentration and RA activity indices, the previous studies revealed conflicting results. The present study showed that serum sclerostin level was significantly correlated with indices of disease activity, which comes in agreement with findings of a previous study on Egyptian patients [37]. Moreover, Brabnikova-Maresova et al [38] reported that serum sclerostin level is significantly correlated with TJC, CRP, and DAS in juvenile patients with RA.…”

Section: Discussionsupporting

confidence: 92%

“…In the present study, serum sclerostin level showed a significant correlation with the radiological score. El-Bakry et al [13] and Ibrahim et al [37] reported significant positive correlation between serum sclerostin and modified Larsen score while Eissa el al [11]. and Mehaney et al [34] reported no significant correlation between serum sclerostin and radiological grading.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum sclerostin in rheumatoid-induced osteoporosis

Gharbia

Hegazy

Elhelaly

et al. 2020

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is characterized by presence of localized and generalized osteoporosis. The mechanism of decreased bone mass is complex and multifactorial, a possible mechanism behind increased bone loss in RA is upregulation of sclerostin. The aim of this work was to evaluate serum sclerostin level in RA patients and its relation with bone mineral density (BMD) and disease activity. Results: Serum sclerostin level in RA patients was significantly higher than the controls (p < 0.001). Osteopenia and osteoporosis were more prevalent in RA patients (22.5% and 7.5% respectively) compared to controls (15% and 2.5% respectively) (p = 0.006). Serum sclerostin level was significantly correlated with tender joint count (p = 0.014), swollen joint count (p = 0.036), erythrocytes sedimentation rate (p = 0.010), C reactive protein serum level (p = 0.025), disease activity score (DAS) 28-ESR (p = 0.018), DAS28-CRP (p = 0.005), and radiological modified Sharp erosion score (p = 0.049). The correlation of serum sclerostin level in RA patients with BMD and with T-score in all sites revealed an inverse relationship with p values insignificant. Conclusion: Serum sclerostin is a major player in bone metabolism as a negative regulator of bone growth through inhibition of Wnt signaling that is largely influenced by the disease activity. Controlling the disease activity is a major factor for prevention of local as well as generalized osteoporosis and is essential for the reparative local and systemic bone health.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Serum sclerostin in rheumatoid-induced osteoporosis

Gharbia

Hegazy

Elhelaly

et al. 2020

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

show abstract

“…Our study found similar ndings to Dhakad et al in India 2019 which did not nd a signi cant association between ESR and sclerostin (17). However, this was different to Ibrahim et al study in Egypt 2015 which found the correlation to be (r = 0.655) (30).…”

Section: Discussioncontrasting

confidence: 87%

The role of sclerostin in rheumatoid arthritis in a Syrian population: a potential indicator of disease activity in newly-diagnosed patients

Hussein

Kakaje

Aboukhais

2022

Preprint

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is an autoimmune disease that can cause irreversible joint deformities and bone erosions. Criteria to diagnose RA includs many laboratory tests with variable sensitivity and specificity. Sclerostin, a Wnt inhibitor, could be associated with the reduced bone formation in RA. This study aims to measure sclerostin level and its association with RA and its activity.Materials and methods: This study contained fifty-eight RA cases and thirty controls who were age and sex matched. All laboratory tests were conducted on both groups, including sclerostin which was measured by enzyme-linked immunosorbent assay (ELISA). The disease activity was assessed using disease activity scores (DAS28).Results: Our results showed that sclerostin levels were significantly higher in RA patients compared to control (p<0.001) but were significantly lower than RA patients with joint deformities (0.026). Sclerostin levels also correlated with CRP (r=0.328, p=0.012), Anti-CCP (r=0.418, p=0.001), tender joint count (r=0.293, p=0.025), and DAS28 (r=0.26, p=0.047). There was not a significant association with other variables such as ESR, and rheumatoid factor. By using receiver operating characteristic (ROC) curve, the best cut-off value of sclerostin was 249.69 pg/ml which showed (AUC 0.910, sensitivity 87.9%; specificity 93.3%) and [Odd Ratio (OR) Value & P-value: 102, P< 0.0001].Conclusion: Sclerostin can be used in addition to other parameters to diagnose RA as it was associated with RA with good sensitivity and specificity. It was also associated in early joint destruction and tenderness.

show abstract

“…This is comparable to a previous study by Gharbia et al [ 18 ], who reported that serum sclerostin levels positively correlated with TJC, SJC, ESR, CRP and DAS28 in patients with RA. Ibrahim et al [ 28 ] also showed a significant positive correlation between serum sclerostin levels and ESR, CRP and DAS28 in RA patients. Similar observations were made by Brabnikova-Maresova et al [ 16 ] in adult patients with juvenile idiopathic arthritis.…”

Section: Discussionmentioning

confidence: 94%

Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy

Szeremeta,

Jura-Półtorak,

Zoń-Giebel

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is associated with significant systemic and local bone loss. The aim of this study was to assess whether or not 15-month tumor necrosis factor α inhibitor (TNFαI) therapy in combination with methotrexate (MTX) affects circulating levels of sclerostin (SOST) in female RA patients. Plasma levels of SOST were measured using immunoassays kits. Baseline SOST levels showed no significant differences between RA patients and control participants. Postmenopausal women with RA tended to have higher sclerostin levels than premenopausal woman with RA. After 15 months of treatment with TNFαI, plasma levels of SOST were decreased. Before starting biological therapy, circulating levels of SOST significantly correlated with the patient’s age (p < 0.05) and the marker of inflammation, such as ESR (p < 0.05). Multivariate regression analysis showed that age was the only significant predictor for baseline SOST levels in women with RA (β = 0.008, p = 0.028, R2 model = 0.293). Moreover, a positive correlation between SOST levels and the 28 joint disease activity score value based on the erythrocyte sedimentation rate (DAS28-ESR) was found at baseline (p < 0.05), as well as after 15 months of biological therapy (p < 0.05). Thus, plasma SOST levels may be helpful for monitoring the efficacy of TNFαI treatment in RA patients. According to our results, TNFαI, in combination with MTX, has a beneficial effect on bone turnover with a significant reduction in bone metabolism marker SOST.

show abstract

Serum sclerostin levels in rheumatoid arthritis

Cited by 6 publications

References 23 publications

Serum sclerostin in rheumatoid-induced osteoporosis

Serum sclerostin in rheumatoid-induced osteoporosis

The role of sclerostin in rheumatoid arthritis in a Syrian population: a potential indicator of disease activity in newly-diagnosed patients

Plasma Sclerostin Levels in Rheumatoid Arthritis Women on TNF-α Inhibitor Therapy

Contact Info

Product

Resources

About